Basket cover image
16 handpicked stocks

Profit Sharers

These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

PFE

Pfizer Inc.

PFE

Current price

$25.32

A global pharmaceutical giant with strong cash flow and a long history of paying dividends.

KO

Coca-Cola Company, The

KO

Current price

$70.13

Its unparalleled brand recognition and global distribution network ensure consistent profits and reliable dividend payments.

JNJ

Johnson & Johnson

JNJ

Current price

$177.80

A diversified healthcare leader that generates substantial cash flow, supporting its long-standing dividend aristocrat status.

About This Group of Stocks

1

Our Expert Thinking

We've identified companies that dominate their markets and consistently generate substantial cash. These aren't just profitable businesses—they're corporations with a proven commitment to rewarding shareholders through generous dividends, offering you both growth potential and steady income.

2

What You Need to Know

These stocks span diverse sectors—from pharmaceuticals and consumer goods to energy and telecommunications. They serve as portfolio stabilizers during market volatility, providing defensive positioning through their reliable dividend payments while still offering exposure to industry leaders.

3

Why These Stocks

Each company was selected after rigorous screening for both profitability and dividend history. We prioritized businesses showing consistent earnings, strong future profit projections, and established patterns of substantial dividend payouts—giving you access to corporate titans that share their success.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+1.96%

Group Performance Snapshot

1.96%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 1.96% over the next year.

10 of 16

Stocks Rated Buy by Analysts

10 of 16 assets in this group are rated Buy by professional analysts.

3.4%

Group Growth

This group averaged a 3.4% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💰

Get Paid While You Wait

These companies don't just promise future growth—they pay you regularly through substantial dividends. It's like earning interest on your investment while still owning a piece of industry-leading businesses.

🛡️

Sleep Better at Night

Market volatility keeping you up? These established profit machines have weathered economic storms before. Their consistent cash generation and commitment to dividends provide stability when markets get rough.

🌱

The Power of Compounding

Reinvesting dividends from these high-yield stocks can supercharge your returns over time. It's the snowball effect that has created wealth for generations of investors who understood the value of dividend income.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

View stocks
Nvidia's China Chip Pivot

Nvidia's China Chip Pivot

Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.

View stocks
Navigating The Autonomous Driving Shakeout

Navigating The Autonomous Driving Shakeout

A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.